Regulatory News: User-Fee Talks, 'Critical-To-Quality' Pilot, Genetic Screening Regs
This article was originally published in The Gray Sheet
The latest FDA-industry user-fee reauthorization talks focused on pre-submissions, IT challenges and more. FDA reported generally positive, early feedback on its "critical-to-quality" inspection pilot program focused on implantable devices that contain batteries. Autosomal recessive carrier screening gene tests are now formally exempt from 510(k) clearance.
You may also be interested in...
During the first round of user fee negotiations, industry questioned FDA's estimated cost of $750 million needed to continue the device user fee program between 2018 and 2022. Lobby groups for the device industry continue to emphasize user fees should supplement congressional appropriations to pay for FDA's review of devices.
Switzerland’s SIX exchange-listed drug development company, Basilea, is moving two new oncology candidates along its R&D pipeline, supported by strong revenues from two partnered anti-infective products.
Recommendations from the Alliance for Regenerative Medicine aim to improve cross-border healthcare to ensure patients can access advanced therapies.